Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer

Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer

Abstract Objective To assess the factors associated with the use of active surveillance (AS) in NCCN favourable intermediate‐risk (FIR) prostate cancer (PCa) patients who received the 17‐gene Genomic Prostate Score (GPS) assay. Material and Methods Contemporary data were collected from academic and...

Full description

Saved in:
Bibliographic Details
Main Authors: Eric Margolis, Benjamin H. Lowentritt, Christopher M. Pieczonka, John P. Bennett, Marina Pavlova, Joao Paulo Zambon, Jack Groskopf, Edward Uchio
Format: Article
Language:English
Published: Wiley 2025-03-01
Series:BJUI Compass
Subjects:
active surveillance
biomarkers
Favourable intermediate‐risk
genomic testing
prostate cancer
Online Access:https://doi.org/10.1002/bco2.494
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items